ABSTRACT Although obesity has multiple etiologies, an overlooked possibility is an infectious origin. We previously identified two viruses, SMAM-1, an avian adenovirus (Ad), and Ad-36, a human adenovirus, that produce a syndrome of visceral obesity, with paradoxically decreased serum cholesterol and triglycerides in chickens and mice. In the two studies presented in this paper, we used nonhuman primates to investigate the adipositypromoting potential of Ad-36. In study 1, we observed spontaneously occurring Ad-36 antibodies in 15 male rhesus monkeys, and a significant longitudinal association of positive antibody status with weight gain and plasma cholesterol lowering during the 18 mo after viral antibody appearance. In study 2, which was a randomized controlled experiment, three male marmosets inoculated with Ad-36 had a threefold body weight gain, a greater fat gain and lower serum cholesterol relative to baseline (P Ͻ0.05) than three uninfected controls at 28 wk postinoculation. These studies illustrate that the adiposity-promoting effect of Ad-36 occurs in two nonhuman primate species and demonstrates the usefulness of nonhuman primates for further evaluation of Ad-36 -induced adiposity. J. Nutr. 132: 3155-3160, 2002. 
Obesity has multiple etiologies, but infectious agents have been consistently overlooked as a possible origin of human obesity. Three animal viruses have been reported to cause obesity in nonprimate species, but have not been implicated in initiating or maintaining obesity in humans (1) (2) (3) . We have now identified two additional viruses, SMAM-1, an avian adenovirus (Ad), and Ad-36, a human adenovirus, that produce obesity in animals (4 -7). In 6 separate experiments, we have shown that these two adenoviruses produce a syndrome of visceral obesity, along with paradoxically decreased serum cholesterol and triglycerides in chickens and mice (4 -8) . A capillary electrophoresis assay designed to detect Ad-36 DNA (9) showed tropism of the virus for adipose tissue of the infected animals (6, 7) . Ad-36 -induced adiposity in animals was hyperplastic and hypertrophic (10) . Preliminary data showed a marked up-regulation of adipocyte differentiation induced by 12) . In humans, serum antibodies to both SMAM-1 and to Ad-36 are associated with obesity and lower cholesterol and triglycerides levels (5, 13) . For ethical reasons, the definitive experiment of injecting humans with Ad-36 to determine a causal role for this virus in human obesity is not possible. Nonhuman primates are the best surrogates for human experiments. In this paper, we used two disparate nonhuman primate species as models in which to study the adiposity promoting potential of Ad-36.
MATERIALS AND METHODS
Study 1: spontaneously occurring antibodies to Ad-36 in rhesus monkeys. Adult male rhesus monkeys (Macaca mulatta) were screened for the presence of spontaneously occurring antibodies to Ad-36, to ascertain their association with longitudinal changes in body weight and cholesterol. Frozen plasma samples from adult male rhesus monkeys (n ϭ 15) were obtained from the Wisconsin Regional 4 Madison, WI. Blood samples and body weight measurements were collected every 6 mo for 90 mo. Monkeys were offered once daily a purified diet (#85387, Teklad, Madison, WI) supplemented daily with a piece of fresh fruit. The composition of the diet is described in Table 1 . Energy value of the diet eaten was ϳ167 kJ [700 kcal/(monkey ⅐ d)]. Monkeys consumed water ad libitum. All monkeys were between 8 and 14 y of age when the first plasma sample available for this study was drawn (baseline sample). Plasma samples were used to determine total cholesterol as well as antibodies to Ad-36, using the neutralization assay described below. For each monkey, the time of first appearance of Ad-36 antibodies, as well as body weight and cholesterol were determined for 18 mo before and after the first antibody appearance.
Study 2: infection of marmosets with Ad-36. In a randomized experiment, adult male common marmosets (Callithrix jacchus) were inoculated with Ad-36 to investigate prospectively the adipositypromoting effect of the virus. Ad-36 antibody-free adult male marmosets (n ϭ 6, age range 2-6 y) were obtained from the WRPRC and were divided into two weight-and age-matched groups (each n ϭ 3) that were individually housed in two separate rooms. Marmosets were fed once daily at 1230 -1400 h ϳ20 g of a specialized diet ( Table 2 Zu Preem Marmoset Diet, Premium Nutritional Products Topeka, KS). Two small chunks of fruit (varied daily, ϳ10 g) were added to provide variety and ϳ5 mL of yogurt was spread on top, providing supplements of vitamin C, cholecalciferol, and calcium. Based on our previous experience, 20 g of the diet is slightly more that the amount consumed by marmosets in a day. To verify ad libitum consumption, it was noted that some food remained in the cage each day. Monkeys consumed water ad libitum. After 4 wk of acclimatization, marmosets were anesthetized with ketamine-xylazine [10 and 0.5 mg/kg, respectively, intramuscular (i.m.)] and inoculated intranasally (i.n.) with tissue culture media containing either Ad-36 virus (5 ϫ 10 5 plaque forming units; Ad-36 group) or no virus (control group). Blood samples were drawn before inoculation (baseline) and also 10, 17 and 28 wk postinoculation and used for antibody screening (using the serum neutralization method described below) and for determination of serum cholesterol and triglycerides. Using the stable isotope dilution method described below, total body fat was determined at baseline and at 28 wk postinoculation, when the experiment was terminated and the monkeys were killed by administration of an i.m. injection of 10 mg/kg ketamine and 0.5mg/kg xylazine followed by an intravenous (i.v.) injection of 100 mg/kg pentobarbital. Visceral fat (intraperitoneal fat) was carefully removed from each carcass and weighed. Samples (ϳ1 g each) of the visceral fat, liver, skeletal muscle, lung and brain of all monkeys were flash-frozen in liquid nitrogen to screen for Ad-36 DNA using a nested polymerase chain reaction (PCR) assay. Virus growth. Ad-36 was obtained from the ATCC. The virus was plaque purified as previously described (6,7) and grown in A549 cells. A working stock of virus was prepared as previously described (6,7) and was titrated on A549 cells, divided into aliquots and stored at Ϫ80°C.
Serum neutralization test for detecting antibodies. Rhesus plasma and marmoset serum were tested for the presence of Ad-36 antibodies. The assay used A549 cells and was conducted as a constant-virus-decreasing-serum method, as previously described (6,7). The absence of cytopathic effect (CPE) of the virus on A549 cells in the presence of the test serum is considered an indication of effective neutralization of the virus and the serum is considered to have antibodies against the virus. Samples were considered antibody positive if the serum titer was Ն1:8. A few rhesus samples demonstrated cell-toxicity up to 1:16 dilutions. For these samples, a more stringent criterion of titer (Ն1:32) was used to denote antibody positivity.
Cholesterol assay. Fasting total cholesterol was determined in duplicate with a cholesterol-oxidase-peroxidase method (Cat # 352-500P; Sigma Chemical) using 10 L of serum.
Development of a nested PCR assay for detection of Ad-36 DNA. Four primers were designed to unique regions of the Ad-36 fiber protein gene for use in nested PCR detection of viral DNA. Sequences of primers were as follows: outer forward primer (5Ј-GTCTGGAAAACTGAGTGTGGATA), outer reverse primer (5Ј-ATCCAAAATCAAATGTAATAGAGT), inner forward primer (5Ј-TTAACTGGAAAAGGAATAGGTA), inner reverse primer (5Ј-GGTGTTGTTGGTTGGCTTAGGATA). DNA was isolated using a QIAamp Tissue Kit (Cat #29304; Qiagen, Valencia, CA). Negative PCR controls were water and DNA from uninfected A-549 cells. Positive PCR control was DNA from Ad-36 infected A-549 cells. DNA was denatured for 2 min at 95°C and subjected to 35 cycles of PCR (94°C for 1 min, 55°C for 1 min, 72°C for 2 min) followed by incubation at 72°C for 5 min. PCR products were visualized on a 1% agarose gel with a size marker. Nested PCR products from positive control (Ad-36 DNA) and infected marmoset brain tissue were sequenced to confirm amplification of targeted region of the gene.
Virus isolation. Adenovirus infection in marmosets was confirmed by collecting fecal samples (wk 4 and 9 after Ad-36 inoculation) and growing the virus on cell cultures as described earlier (7). Body composition analysis by stable isotope dilution method. Blood (1 mL) was drawn followed by i.v. administration of 0.1 g/kg deuterium oxide. The dose was determined by weighing the syringe before and after administration. A second blood sample was obtained 2 h after the dose. Equilibration time for the stable isotope is ϳ60 -75 min for rhesus monkeys; therefore, 2 h was considered an adequate equilibration period for the marmosets. Isotope dilution spaces were determined by forcing the serum through a 100,000-Da exclusion filter and distilling and reducing over zinc for mass spectrometric determination of the isotopic abundance. Dilution space was calculated from the isotopic enrichment of the 2-h sample relative to the predose sample. Fat-free mass was calculated from total body water, assuming a hydration ratio of 0.732. Body fat was calculated by subtracting fat-free mass from the total body mass. (14) . When Y was regressed on Ad-36 status, monkey, and the polynomials of age in the mixed effects model, the effect of Ad-36 status was significant (F ϭ 8.14; df ϭ 1,96; P ϭ 0.005). Thus, there was a clear effect of Ad-36 status on combination of weight and cholesterol. We then examined each dependent variable separately.
Univariate tests. Univariate tests were conducted only when the multivariate test was significant. Each dependent variable (weight and cholesterol) was regressed on Ad-36 antibody status, monkey and polynomials of age in a mixed-effect model. Study 2. Groups were compared using Student's t test. Values in the text are means Ϯ SD.
RESULTS
Study 1: spontaneously occurring antibodies to Ad-36 in rhesus monkeys. During the 90-mo period, all 15 monkeys showed Ad-36 antibodies at some point in time. Because blood samples were obtained at 6-mo intervals, the exact date of seroconversion during the preceding 6 mo of the first positive sample is unknown. The appearance of antibodies in the plasma did not demonstrate an annual pattern. Of 15 monkeys, 8 were seronegative at baseline. Only these monkeys were included in the statistical analysis to compare the body weights and cholesterol levels before and after the first appearance of Ad-36 antibodies. The remaining 7 monkeys were seropositive for Ad-36 antibodies at baseline and were excluded from statistical analysis.
Before separate univariate tests were conducted, a multivariate test (see Methods) was conducted that indicated a clear effect of Ad-36 status on the combination of weight and cholesterol (P ϭ 0.005).
The monkeys were completely free of antibodies from Ϫ18 to Ϫ6 mo before the first positive sample; this was designated as the "baseline" period, whereas the period from ϩ6 to ϩ18 mo after seroconversion was designated as the "postinfection period." Body weight and plasma cholesterol level changes for 18 mo before and 18 mo after the first appearance of Ad-36 antibody are presented in Figures 1 and 2 . Time point "0 mo" denotes the first antibody positive serum sample for each monkey.
Weight. Body weight changed little during the baseline period, decreasing by ϳ0.3% (0.04 Ϯ 1.5 kg; P ϭ 0.87). In contrast, the body weight increased by ϳ10% in 6 mo and by ϳ15% (1.7 Ϯ 0.8 kg, P Ͻ 0.03) at 18 mo during the "postinfection" period ( Fig. 1) . In the full statistical model, the effect of Ad-36 antibody status was significantly associated with weight gain (F ϭ 5.47; df ϭ 1,96; P ϭ 0.021). The parameter estimate for the effect of Ad-36 antibody status was 0.81 kg, indicating that the generation of Ad-36 antibodies was associated with an increase in body weight of 0.81 kg.
Cholesterol. Plasma cholesterol levels were stable during the baseline period, but decreased by ϳ23% (P ϭ 0.06) during the 6 mo immediately after the appearance of Ad-36 antibodies and remained low for at least 18 mo during the postinfection period (Fig. 2) . In the full statistical model, the effect of Ad-36 antibody status was significant (F ϭ 5.33; df ϭ 1,96; P ϭ 0.023). The parameter estimate for the effect of Ad-36 antibody status was 0.49 mmol/L, indicating that the generation of Ad-36 antibodies was associated with a decrease in FIGURE 1 Adenovirus (Ad)-36 antibody appearance and body weight change in rhesus monkeys. Values are mean Ϯ SD; n ϭ 8. Plasma samples from adult male rhesus monkeys were collected every 6 mo for 90 mo and tested for antibodies to Ad-36. Body weights are plotted for the 18 mo before the onset of Ad-36 antibodies (Ϫ18, Ϫ12 and Ϫ6 mo) and after the monkeys became antibody positive (0, 6, 12 and 18 mo). *Different from the body weight at Ϫ6 mo (the last antibody-free value), P Ͻ 0.05.
FIGURE 2
Adenovirus (Ad)-36 antibody appearance and plasma cholesterol change in rhesus monkeys. Values are mean Ϯ SD, n ϭ 8. Plasma samples from adult male rhesus monkeys were collected every 6 mo for 90 mo and tested for antibodies to Ad-36. Plasma cholesterol values are plotted for the 18 mo before the onset of Ad-36 antibodies (Ϫ18, Ϫ12 and Ϫ6 mo) and after the monkeys became antibody positive (0, 6, 12 and 18 mo). *Different from the body weight at Ϫ6 mo (the last antibody-free value), P Ͻ 0.05. plasma levels of cholesterol by 0.49 mmol/L. Thus, when controlled for age, and after the first appearance of Ad-36 antibody, the rhesus monkeys had greater body weights and lower cholesterol levels.
Study 2: infection of marmosets with Ad-36. Body weights of both groups did not differ at the time of inoculation (336.4 Ϯ 19.8 g vs. 346.3 Ϯ 27.8 g, P ϭ 0.65; for the Control and the Ad-36 -infected groups, respectively). The serum neutralization assay showed an absence of Ad-36 antibodies in the control group at all times during the experiment. Two of the three Ad-36 -inoculated marmosets were antibody positive at both 10 and 17 wk postinoculation. Ad-36 could not be isolated from the fecal samples of the control group at any time during the study. However, the infective virus was isolated at both 4 and 9 wk postinoculation from the fecal samples of the two Ad-36 inoculated marmosets that had detectable Ad-36 antibodies. The nested PCR assay, however, detected Ad-36 DNA in the adipose tissue, liver, skeletal muscle, lung and the brain samples of all three Ad-36 inoculated marmosets, but not in any monkey in the control group. The nested PCR assay results for the adipose tissue of the two groups are presented in Figure 3 . Isolation of Ad-36 virus from fecal samples and the presence of viral DNA in the tissue of all infected males demonstrated that marmosets were readily infected with Ad-36.
At 28 wk after inoculation, the Ad-36 group had greater body weight gain (41.4 Ϯ 11.2 g vs. 10.8 Ϯ 13.4 g, P ϭ 0.039; Fig. 4 ) and total body fat gain (36.3 Ϯ 6.1 g vs. 23.0 Ϯ 3.0 g, P ϭ 0.013) than controls. The mean weight gain of 41 g represented a 12% increase in the Ad-36 group compared with a 3.2% increase in the control group, a threefold difference. The Ad-36 group tended to have more visceral fat than controls (7.3 Ϯ 2.5 g vs. 4.4 Ϯ 0.9 g, P ϭ 0.089). Despite the gain in fat mass and body weight, serum cholesterol levels were lower in the Ad-36 group than in controls (change from baseline: Ϫ0.79 Ϯ 0.28 mmol/L vs. 0.10 Ϯ 0.08 mmol/L, P ϭ 0.006; Fig. 5 ). The change in serum triglycerides from baseline tended to be greater in infected marmosets that in controls (Ϫ0.52 Ϯ 0.23 mmol/L vs. 0.14 Ϯ 0.53 mmol/L, P ϭ 0.122).
DISCUSSION
Although 50 types of human adenoviruses are deposited with the ATCC, Ad-36 is the first reported to cause obesity in animals (6,7). Ad-36 is serologically different from at least 47 of the other 49 human adenoviruses (15) (16) (17) (18) (19) (20) (21) (22) ; it was first isolated in 1978 in Germany from the feces of a diabetic girl suffering from enteritis (17). Relative antigenic uniqueness was one of the main reasons for selecting Ad-36 to test for the adiposity-promoting effect.
The concept of virus-induced obesity is of greater importance if shown to be relevant to human obesity. Although we have demonstrated the adipogenic and hypolipidemic effects of a human virus in animals such as chickens and mice, we can not conclusively extrapolate the results, without verification, to human obesity. Differences in lipid metabolism between lower animals and primates preclude such a direct extrapolation. For instance, the energy metabolism of chickens is based on free fatty acids, not glucose, and insulin is of minor importance. Such metabolic differences clearly warranted the use of a higher model to establish the relevance of the findings to human obesity. In addition, because of ethical reasons, humans can not be infected experimentally with Ad-36 to verify its adipogenic effect directly. Therefore, we decided to use nonhuman primate species as the best way of determining the relevance of Ad-36 in human obesity. 
FIGURE 4
Cumulative body weight gains in marmosets after inoculation with adenovirus (Ad)-36. Values are means Ϯ SD, n ϭ 3 per group. *Different from control, P Ͻ 0.05.
FIGURE 5
Cumulative changes in serum cholesterol in marmosets after inoculation with Ad-36. Values are means Ϯ SD, n ϭ 3 per group. *Different from control, P Ͻ 0.05.
In our rhesus monkey study, the fact that all of the 15 monkeys had Ad-36 antibodies at some time during the 90-mo period suggests a covert epidemic of Ad-36 infection in the rhesus monkey colony at WRPRC. The source of Ad-36 infection in monkeys is not yet known. However, transmission from humans is a possibility. Although most adenoviruses are species specific in their replication cycle, we have recovered infectious Ad-36 virus from Ad-36 -infected chickens (6, 7) and have detected naturally occurring antibodies to Ad-36 in chickens as well as rats (unpublished data). The ability of Ad-36 to infect and replicate in widely disparate vertebrate species is in itself unusual. Therefore, the presence of naturally occurring antibodies in rhesus monkeys to a human adenovirus is not very surprising.
Serum neutralization is considered the "gold standard" to specifically detect neutralizing antibodies. In addition to the previously reported minimal antigenic cross-reactivity of Ad-36 (16,-22) , we confirmed that Ad-36 does not cross-react with other human adenoviruses such as Ad-2, Ad-31 or Ad-37 (unpublished data). Therefore, it is unlikely that the antibodies detected in the rhesus monkey plasma that neutralized Ad-36 were antibodies to other human adenoviruses. Antibodies to simian adenovirus(es) that may cross-react with Ad-36 are a possibility, although cross-reactivity between a simian adenovirus and Ad-36 has not been reported.
In rhesus monkeys, a positive correlation of age with body weight and serum cholesterol would have been expected. The increase in body weight and drop in cholesterol during the postinfection period that persisted even after controlling for age supports our hypothesis that these changes were associated with the appearance of Ad-36 antibodies.
A comparison of body weight and plasma cholesterol changes between antibody positive and antibody-free monkeys would have been optimal to eliminate the effect of age on these variables. However, all 15 rhesus monkeys developed Ad-36 antibodies at different times during the study period, thus precluding such a comparison. Nevertheless, the following measures ensure that the changes in body weight and cholesterol observed were not age related.
The age of the monkeys ranged from 8 to 14 y. The age of the first appearance of antibodies varied among the monkeys. Regardless of the age of seroconversion, there was little change in body weights or plasma cholesterol in the 18 mo before the first appearance of antibodies. Thus, although the period before the onset of antibodies represents different ages for individual monkeys, their body weights were stable during this period. Such a stabilization of body weight is expected in adult rhesus monkeys who have completed their growth. Also, an age-related decline in plasma cholesterol is not expected in freely fed rhesus monkeys. In effect, each monkey acted as his own control for body weight and cholesterol comparisons before and after the seroconversion. As stated earlier, we further ascertained the age effect by controlling statistically for age, and found a clear effect of seroconversion on body weight and cholesterol that was independent of age. These measures demonstrate that the observed changes were not age related.
In the marmoset experiment, the persistence of Ad-36 DNA in various tissues of all marmosets 6 mo postinfection is an important finding, demonstrating the spread of Ad-36 in their bodies, even though one marmoset failed to generate detectable levels of antibodies. In addition, the presence of Ad-36 DNA in the adipose tissue is particularly intriguing because our preliminary data showed Ad-36 induced up-regulation of 3T3-L1 cell (rodent embryonic preadipocytes) differentiation (11,12). Future experiments should investigate the Ad-36 -induced up-regulation of fat cell differentiation as a possible mechanism of Ad-36 -induced obesity in monkeys. Similarly, Ad-36 -induced hypothalamic damage is another possible mechanism that should be investigated. Canine distemper virus may promote obesity in mice by inducing hypothalamic damage (1). Although we did not find histopathological hypothalamic lesions in Ad-36 -infected mice in an earlier study (6) , the presence of Ad-36 DNA in the brains of the infected group warrants such an investigation in marmosets.
Considering the very small starting body weights of the marmosets, the mean postinoculation weight gain of 41g represents a 12% increase in the Ad-36 group, which is approximately threefold greater than the 3.2% mean weight gain in the control group. Also, the Ad-36 group had an 11.5% total fat gain vs. 6.8% in the control group and 66% more visceral fat than the controls. Given the very small size of marmosets, these findings are of major biological importance.
The data presented in this paper suggest that Ad-36 plays a role in increasing body weight in nonhuman primates such as rhesus monkeys and marmosets; either animal could be used as a surrogate model with which to study the role of Ad-36 in human obesity. However, as a model, marmosets appear to have some advantages over rhesus monkeys because they are smaller, easier to house and handle and less expensive. In addition, in our initial screening of monkeys from the WRPRC colony for Ad-36 antibodies, Ͻ 4% of the marmosets were antibody positive. This very low prevalence of Ad-36 antibodies in marmosets gives a much better chance to select antibody-free marmosets for a prospective study (rhesus monkeys from the WRPRC had much greater and frequent contact with humans, whereas the marmosets are housed in a more controlled environment to prevent inadvertent infections). Additionally, the fact that marmosets have a life-expectancy of ϳ8 y (vs. 30 -40 y for rhesus monkeys) means that in future prospective studies, marmosets could be tracked relatively easily during their complete life-cycle to ascertain the long-term consequences of Ad-36 infection.
A survey from three different states in the United States showed a 30% prevalence of Ad-36 antibodies in obese but only a 5% prevalence of the antibodies in nonobese subjects (13) . The antibody-positive obese subjects also had significantly lower serum cholesterol levels (13) . Body weight gain and hypocholesterolemia in response to Ad-36 infection in two divergent primate species support the hypothesis that the virus may play a causative role in human adiposity and demonstrate the suitability of the two animal models for further of the phenomenon. In addition, the relationship of Ad-36 with body composition and serum lipids in these models suggests that in the future, investigators studying body weight, obesity, obesity treatment or evaluation of serum lipids in rhesus monkeys or marmosets would be wise to take into account the status of infection with Ad-36 because Ad-36 may add extraneous variance to the outcome.
